PRESS RELEASES

PRESS RELEASES

DateTitle 
03/30/20
- Phase 2 stage of its Phase 1b/2 clinical trial of AST-008 is still expected to begin in 2nd quarter - Research labs open for critical R&D activity; progress continues on Friedreich’s Ataxia development and collaboration programs - Preliminary unaudited cash, cash equivalents, and short-term
03/03/20
- Friedreich’s ataxia chosen as first neurological indication - Reported Phase 1b data for lead immuno-oncology candidate in solid tumors -Development partnership with Allergan in hair loss disorders - Cash and short-term investments on Dec. 31, 2019 of $110.8 million CHICAGO & CAMBRIDGE, Mass.
03/02/20
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that its chief executive officer, David Giljohann , will give a company update on Wednesday,
Print Page  | RSS Feeds  | E-mail Alerts  | IR Contacts